Dyadic enters recombinant albumin partnership with Proliant; $1.5M upfront milestone payments + profit share

DYADIC INTERNATIONAL INC

Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.
First product (recombinant human serum albumin) expected to launch in first half of 2025.
Partnership targets ~$6B serum albumin market for cell culture, vaccine, medical device, diagnostic segments.
Dyadic's COO states agreement demonstrates strategy to commercialize products and generate near-term revenue in Alternative Proteins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.